• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » The rising popularity of a more expensive varicose vein treatment | MassDevice On Call

The rising popularity of a more expensive varicose vein treatment | MassDevice On Call

December 21, 2010 By MassDevice staff

MassDevice On Call

The rising popularity of a more expensive varicose vein treatment. Growing in popularity are lasers and radiofrequency ablation to destroy veins, which cost $2,500 to $3,000 per procedure, compared with about $1,200 to $1,500 for surgical stripping, according to the American American Society for Dermatologic Surgery, reports The Wall Street Journal‘s Health Blog.

Killing cancer by taking out hardier cells. Scientists have identified in recent years a subset of cells in a variety of cancers that appear resistant to conventional treatments such as chemotherapy and radiation. A growing number of researchers believe these hard-to-kill cells are a major reason why cancer treatments often fail, according to The Wall Street Journal.

White House posts standards for scientific integrity in government agencies. The executive branch issued a memorandum to the heads of departments and agencies, such as the Food & Drug Administration, that provides further guidance to executive branch leaders as they implement administration policies on scientific integrity. The new memorandum describes the minimum standards expected as departments and agencies craft scientific integrity rules appropriate for their particular missions and cultures, including a clear prohibition on political interference in scientific processes and expanded assurances of transparency, according to The White House Blog.

Sanofi to buy Avila Therapeutics for $800M. The dealmaking machine that is Sanofi-Aventis is at it again, signing an oncology drug pact with Avila Therapeutics in Waltham, Mass. worth $40 million up front and up to $154 million in milestone payments per program. Overall, the deal is valued at $800 million, according to FierceBiotech.

Budget could starve health reform. Here’s the problem with funding 2011’s government using 2010’s budget: Funding the government at 2010 levels means starving some signature accomplishments — like healthcare reform — of implementation funds, according to the Washington Post’s Ezra Klein.

More biotech M&A for Gilead. Gilead Sciences (NSDQ:GILD), the Foster City, Calif.-based biotech company, has agreed to acquire Arresto Biosciences, the Palo Alto, Calif.-based company whose lead drug candidate is an antibody for idiopathic pulmonary fibrosis, for $225 million plus future milestone payments based on product sale levels, according to Xconomy San Francisco.

Nurses plan HCA strike in California. Hundreds of nurses plan to strike five hospitals in Southern California owned by for-profit hospital giant HCA Inc. over the Christmas holiday to protest stalled contract talks, reports the San Francisco Chronicle.

Neuronetrix goes to trials with Alzheimer’s detector. Neuronetrix in Louisville, Kentucky, has begun a multi-center clinical trial of its COGNISION system, a headset that measures electrical field potentials of the brain while a sound pattern is played to the subject, for early detection of Alzheimer’s, according to the medGadget blog.

Silence… for $20.7M. Former Pfizer CEO Jeff Kindler had to sign a vow of silence that prevents him from saying certain “truthful statements” about the company in order to receive his $20.7 million severance package, according to an SEC disclosure, BNET reports.

Virtual beagle tests pharmaceuticals. Studies on beagle dogs can be used by scientists to gauge the absorption, distribution, metabolism and excretion (ADME) properties of a medicine, prior to testing on humans. Simcyp Ltd. announced that it extended the capabilities of its animal Simulator allowing modeling and simulation studies involving the administration and testing of medicines to be performed in the virtual beagle dog, the company said.

Material from MedCity News was used in this report.

Filed Under: Healthcare Reform, News Well

In case you missed it

  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D
  • Abbott reports positive data on heart valve therapies
  • OncoRes Medical raises another $12.5M
  • NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia
  • Inogen appoints Agnes Lee as senior VP of investor relations, strategic planning
  • Google Health hires FDA’s chief digital health officer
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says

RSS From Medical Design & Outsourcing

  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS